EpiVax releases AI‑optimized immunogenicity prediction models, advancing in silico safety testing for biologics
Executive summary: EpiVax launched AI‑optimized models for predicting immunogenicity of biologics within its ISPRI™ in silico platform on September 3, 2026. The models improve the precision and turnaround time of immunogenicity screening, helping biopharma companies lower the risk of clinical trial failures and accelerate drug development timelines.
Who is involved: EpiVax Inc., its ISPRI™ platform, and biopharma clients that use in silico immunogenicity testing.
Likely next: Anticipated broader adoption of the ISPRI™ AI models by drug developers and potential regulatory qualification submissions for the new models.
EpiVax announced the availability of new AI‑enhanced models for its ISPRI™ platform on September 3, 2026, building on the JanusMatrix™ model launched the prior day. The update aims to improve the accuracy and speed of immunogenicity risk assessments for biotherapeutics, a step that could reduce costly late‑stage trial failures. By integrating tighter AI workflows, EpiVax positions its platform as a more attractive option for pharma firms seeking to streamline preclinical safety evaluation.
Timeline
- — EpiVax lance des modèles optimisés par l'IA pour la prédiction de l'immunogénicité (PR Newswire)
Analysis — what this means
Sectors affected
- Biotechnology immunogenicity prediction
- AI‑driven drug discovery
- Pharma R&D
Historical parallels
- EpiVax launched AI‑enhanced models for immunogenicity prediction on September 2, 2026 (PR Newswire)